PB College Seminars Series
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

Psychiatric Bulletin (1994) 18: 335-337. doi: 10.1192/pb.18.6.335
© 1994 The Royal College of Psychiatrists
This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mullen, R.
Right arrow Articles by Smith, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mullen, R.
Right arrow Articles by Smith, S.

Perception of equivalent doses of neuroleptic drugs

R. Mullen, Clinical Research Worker, A.W. Caan, Audit Research Co-Ordinator and S. Smith, Registrar in Psychiatry

The Maudsley Hospital, London SE5 8AZ

An anonymous questionnaire was sent to 67 senior and junior psychiatrists enquiring about their perception of equivalent antipsychotic dosages of three commonly used neuroleptic drugs. Thirty-one questionnaires were returned and revealed a wide variation in perceived potencies for the specific drugs. Increased experience in psychiatry was not associated with a decreased variation. On average clinicians saw haloperidol and flupenthixol decanoate as substantially less potent, relative to chlorpromazine, than the available literature would suggest.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1994 The Royal College of Psychiatrists.